Geojit raises target for Sun Pharma stock to INR 2,070.00

Published on 10/13/2026 at 13:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 fiscal 2027 revenue rose 10.50 percent to INR 153.00 billion. Sun Pharma stock stood at INR 1,770.70 on October 13, 2026, up 0.61 percent on NSE.

Geojit Investments raised its Sun Pharma target from INR 1,933.00 to INR 2,070.00 in a September 21, 2026 report.
Q1 fiscal 2027 revenue rose 10.50 percent year over year to INR 153.00 billion.
Sun Pharma stock stood at INR 1,770.70 on NSE on October 13, 2026 at 3:28 p.m. IST, up 0.61 percent versus the NSE close of October 12, 2026.
The stock had a price to earnings ratio of 35.13 and market capitalization of INR 4.2 trillion as of October 13, 2026.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Geojit Investments raised its target for Sun Pharma stock from INR 1,933.00 to INR 2,070.00 in a report dated September 21, 2026. According to DSIJ, the target was based on 30 times fiscal 2028 adjusted earnings per share of INR 69.00, putting the target 16.90 percent above the NSE price of INR 1,770.70. Sun Pharma stock stood at INR 1,770.70 on NSE on October 13, 2026 at 3:28 p.m. IST, up 0.61 percent versus the NSE close of October 12, 2026 at INR 1,760.00.

Revenue growth reaches 10.50 percent

Sun Pharma reported revenue from operations of INR 153.00 billion in the first quarter of fiscal 2027, up 10.50 percent from the year-earlier period. The same DSIJ report said earnings before interest, taxes, depreciation and amortization rose 5.50 percent to INR 42.96 billion, while the margin declined to 28.10 percent.

Reported profit after tax rose 26.40 percent to INR 29.11 billion in the same quarter. The margin comparison was affected by the absence of a one-off contribution from Lenalidomide sales in the year-earlier period, according to DSIJ.

Stock remains 13.50 percent below high

NSE data put the October 13, 2026 52-week range at INR 1,583.70 to INR 2,046.90. At INR 1,770.70, Sun Pharma was 13.50 percent below its 52-week high and 11.81 percent above its 52-week low, while its year-to-date performance stood at 2.68 percent.

Comparison with peers on October 13, 2026

Sun Pharma: up 0.61 percent, price to earnings ratio 35.13, market capitalization INR 4.2 trillion

Cipla (NSE, INR): up 1.40 percent, price to earnings ratio 31.88, market capitalization INR 1.1 trillion

Dr. Reddy's Laboratories (NSE, INR): up 0.86 percent, price to earnings ratio 31.23, market capitalization INR 1.0 trillion

Price and leverage remain key variables

Geojit's September 21, 2026 target places the valuation discussion above the current NSE quote, but the report also highlighted execution risks around the proposed Organon acquisition. The broker said completion was targeted for the fourth quarter of fiscal 2027 and identified specialty medicines, domestic formulations and integration progress as important operating factors.

Sun Pharma's stock price stood at INR 1,770.70 on NSE on October 13, 2026 at 3:28 p.m. IST, versus the NSE close of INR 1,760.00 on October 12, 2026. Its market capitalization was INR 4.2 trillion and its price to earnings ratio was 35.13 on October 13, 2026.